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Interruption of Pregnancy in 
Women with the Uterine Scar: 
Potential Risks
Galina Dikke and Vladimir Ostromenskiy
Abstract
Summary objective: To assess the risks and identify effective and safe methods 
of abortion in women with uterine scar. Material: Literary sources published in the 
databases of Medline, PubMed, and others, of which 57 are included in this review. 
The main provisions: Termination of pregnancy in women with a scar on the uterus 
involves the use of any available method. For women with a scar on the uterus, it 
is necessary to prepare the cervix before a surgical abortion in all terms. Abnormal 
implantation of the embryo within the fibrous tissue of the scar after caesarean sec-
tion can cause life-threatening bleeding of the mother during or after the termina-
tion of the pregnancy. Surgical excision of the affected area by hysteroscopic access, 
as well as transvaginal or transabdominal local administration of Methotrexate with 
or without an additional intramuscular dose of the same drug, seems to be optimal 
from the point of view of minimizing the frequency of complications. Conclusion: 
A scar on the uterus after caesarean section presents a high risk of abnormal attach-
ment of the ovum and fatal bleeding during abortion.
Keywords: medical abortion, surgical abortion, uterine scar, bleeding
1. Introduction
Interruption of pregnancy in patients with uterine scar, as well as in women 
without it, can be artificial (in early and late pregnancy period if medically 
required, and also in pregnancy period exceeding 22 weeks—at still birth) or 
spontaneous.
Although there is no doubt presently that now caesarean section is quite a safe 
procedure, it still presents a certain risk not only for the subsequent pregnancy and 
confinement, but also in case of its interruption.
Interruption of pregnancy in women with uterine scar assumes the use of any 
accessible method [1]. However, the abortion made by the method of uterine curet-
tage in the interval period aggravates the forecast. The risk of scar inadequacy in 
this case increases 1.5 times.
Recently, substantial growth of registered cases of localisation of ovum in the 
uterine scar after previous caesarean section has been observed [2]. After one or 
several caesarean section operations, the specific localisation of the chorion, such as 
presentation and scar increta, can be a reason of serious complications during and 
after interruption of pregnancy.
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2.  Medicamentous interruption of pregnancy in women with an 
uterine scar
The technology of medicamentous interruption of pregnancy in the early 
period, the used preparations and their doses do not differ for groups of women 
having a uterine scar and those without it.
It is marked in medical periodicals that the use of Mifepristone and Misoprostol 
for interruption of pregnancy during the period not later than 49 days of amenor-
rhoea in women with a uterine scar is safe and effective [3, 4]. Not a single case of 
uterine rupture at the place of the scar or increased frequency of other complica-
tions is described for medicamentous interruption of pregnancy in early period in 
case of caesarean section in the anamnesis, in comparison with the women who did 
not undergo operative uterine treatment [5].
The preceding caesarean section operations are deemed to be a uterine rupture 
risk factor in case of interrupting gestation at 13 weeks and later. However, the 
study of abortion results in the second trimester, induced by Misoprostol, in 720 
women with one or several prior caesarean section intervention shows that the 
use of the medicamentous method does not cause more frequent complications in 
comparison with the women with non-operated uterine (the absolute risk of uterine 
rupture is <0.4%) [1].
Thus, the presence of a uterine scar after the previous caesarean section is not 
a contraindication for medical abortion at early pregnancy and does not involve 
increased frequency of complications.
3.  Recommendations for medical abortion in women after caesarean 
section in case of localisation of the chorion/placenta outside the 
uterine scar
• The most essential data for medicamentous interruption of pregnancy relate 
to the application of Misoprostol, but the level of evidence is low. The doses 
of Misoprostol in case of late pregnancy interruption should be twice lower 
for the women with uterine scar, in comparison with the women without it 
(Table 1) [6].
• The use of Mifepristone or hygroscopic dilators is not counter-indicative [7].
• In case of interruption of late pregnancy or foetus death in patients with the 
uterine scar, in most cases induction of confinement is more preferable than 
planned caesarean section irrespective of the number of past caesarean section 
operations (the recommendation of a professional consensus).
• In case of still birth, at the period of 27–28 and over 28 weeks of gestation, 
Misoprostol is not used for medicamentous abortion [6].
• The presently practiced options of medical treatment of women with  
incomplete or missed abortion include expectant management (for women 
with spontaneous miscarriage, with no excessive uterine bleeding, with 
stable haemodynamics and no signs of infection), medicamentous treatment 
(usually Misoprostol or Mifepristone/Misoprostol) or surgical treatment 
(vacuum aspiration or dilation and curettage). An important factor in choos-
ing a method for management of spontaneous miscarriage is the woman’s 
preference [8, 9].
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• In case of non-developing pregnancy up to 63 days of amenorrhoea, only the 
use of Misoprostol at a dose of 800 mcg vaginally or 600 mcg sublingually 
is possible. Administration can be repeated in 3 hours, if necessary (2 doses 
maximum).
• The patients with a uterine scar willing to interrupt the pregnancy or those 
with unexpected miscarriage, need all-round detailed consultation, and the 
doctor must consider all variants of administration, their advantages and risks. 
Individual approach is necessary, with account of the obstetric anamnesis, 
comorbid diseases and potential complications, such as haemorrhage and 
uterine rupture constituting a life-threatening situation [1].
Advanced pregnancy, no previous confinement in the past medical history and 
previous confinement by caesarean section result in extended duration of abortion.
The mother’s age, body mass index, race and the interval between administra-
tion of Mifepristone and Misoprostol do not affect the duration of the abortion.
Preparation of the cervix before surgical abortion is recommended to all 
women with the pregnancy exceeding 12–14 weeks. The preparation can be recom-
mended as well to women with high risk of cervix trauma or uterine perforation 
at any pregnancy period. For this purpose, osmotic dilators (laminaria tents, 
Dilapan-S), pharmacological medications (Mifepristone, Misoprostol) or their 
combinations are used.
Preparation Dose Method of 
administration
Frequency of administration
Up to 49 days* 400 μg Orally One time
50–63 days* 800 μg Vaginally*** One time
64–84 days* 800 μg 
400 μg
Vaginally*** (first 
dose), subsequently 
vaginally*** or 
sublingually
Every 3 hours, up to 4 doses
If abortion fails to occur within 14 days, then vacuum aspiration is administered
13–24 weeks* 200 μg Vaginally*** (first 
dose), sublingually 
(subsequent doses)
Every 3 hours, up to interruption of 
pregnancy
If abortion fails to occur within 24 hours, then administration of Mifepristone is to be repeated in 3 hours 
after the last dose of Misoprostol, and after 12 hours-Misoprostol
25–26 weeks* 100 μg Vaginally,*** buccally 
or sublingually
Every 4 hours (in case of still birth-
after 6 hours), up to interruption of 
pregnancy
An extra dose Misoprostol is applied if the placenta did not come off in 30 minutes after foetus expulsion
27–28 weeks** 100 μg Vaginally,*** buccally 
or sublingually
Every 4 hours, up to interruption of 
pregnancy
Over 28 weeks** 50 μg Vaginally,*** buccally 
or sublingually
Every 6 hours, up to interruption of 
pregnancy
An extra dose Misoprostol is applied if the placenta did not come off in 30 minutes after foetus expulsion
*Misoprostol is applied in 24–48 hours after administration of Mifepristone at a dose 200 mg one time ingestion.
**Is not applied in case of still birth.
***To exclude vaginal application in case of haemorrhage or signs of infection.
Table 1. 
Medical abortion schemes with application of misoprostol in women with a uterine scar [6].
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The advantages of osmotic dilators over Mifepristone or Misoprostol have been 
identified in terms of efficiency [10–12], of Dilapan-S over laminaria tents in the 
accepted “one-day” procedures for cervical dilatation [13] and in respect of the 
use of Misoprostol in addition to osmotic dilators in case of cervix deformation or 
pregnancy period exceeding 16 weeks [14].
In some cases, osmotic dilators are used more extensively, for instance, in 
treatment of teenagers, non-parous women or women with cervical scars. It is also 
recommended to increase the number of dilators with the progress of pregnancy 
period. As compared with laminaria tents, by-half-less number of Dilapan-S rods 
is required because of wider cervical dilatation [14]. Two rods are recommended at 
the 13–15-week pregnancy period, three at 16–18-week period and four at 18 weeks-
period and further (though only few proofs substantiate this recommendation). 
After 18 weeks, administration of Dilapan-S is recommended one time overnight 
[15]. However, one rod inserted 3–4 hours prior to the dilation and evacuation can 
be sufficient for the pregnancy period not exceeding 18 weeks.
The methods combining osmotic dilators and Misoprostol are efficient owing to 
the shortest known time to yield effect (from 2 to 4 hours). The possibility to com-
plete the procedure within 1 day for the 18–22 weeks pregnancy period was demon-
strated by Lyus R. et al., who used 3 Dilapan-S rods and 400 μg of Misoprostol. The 
average time for preparation of the cervix was 3 hours 40 minutes, and the average 
time of the manipulation—10 minutes [16].
The preparation of the cervix at the 17–22 weeks period of pregnancy requires 
greater time, sometimes 2–3 days (with replacement of dilators) [17]. The compari-
son of Dilapan-S with laminaria tents showed that the adequate cervical dilation on 
the 2nd day was achieved in 98 and 56% of women respectively [18].
4. Chorion ingrowth into the uterine scar in early pregnancy
Accreta, increta and percreta of the chorion is characterized by their accretion 
to the uterine myometrium without any intermediate decidual membrane, with 
different extent of their invasion into the myometrium. In the scientific literature, 
the term “placenta accreta” incorporates “placenta increta et percreta”.
4.1 Epidemiology
The chorion ingrowth into the uterine scar during the early pregnancy is diag-
nosed extremely seldom and varies between 1/110 and 1/2500 of pregnancy cases 
[19]. Some authors note a gradual increase in placentation anomalies, which coin-
cides in proportion with the increased frequency of caesarean section operations: in 
1970s years the figure was 1/70,000 [20], and in 2005—1/533 [21]. The meta-analysis 
made for the period from 1972 to 2011 describes 47 cases of diagnosed placentation 
anomalies in the first trimester and at the beginning of the second trimester [22].
4.2  Complications of artificial abortion in case of chorion increta into the 
uterine scar
According to Abbas et al. [23], placenta accreta is usually not identified in the 
first trimester of pregnancy, and the diagnosis concerning this pathology is made 
retrospectively for patients with excessive haemorrhage that arises during the 
uterine curettage which is secondary in relation to the invasion of chorionic villi in 
the myometrium [23]. Some observations of tardive uterine bleeding in some weeks 
and even several years after the abortion [24, 25] have been described.
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According to Jang et al., the clinical manifestation may also include spontaneous 
uterine rupture with clinical development of “sharp belly” and haemoperitoneum 
[26]. Spontaneous uterine rupture was registered in 15 out of 47 cases (32%) 
described in the meta-analysis; most of them were asymptomatic and were accom-
panied by intra-abdominal haemorrhage and collapse [22].
The form of abnormal embryo implantation in the scar fibrous tissue after the 
caesarean section, dangerous for the mother’s life, can lead to ectopic pregnancy 
(localisation of the ovum between the uterus and it serous membrane). The diag-
nostics of such condition with the help of ultrasonography does not represent any 
difficulties and is made for pregnancy period of 5–12 weeks, with the time interval 
between the last caesarean section and the ectopic pregnancy from 6 months to 
12 years [27].
The complications associated with chorion increta also include fistulisation, 
infection, perinatal and maternal death [28].
4.3 Diagnostics of chorion increta into the uterine scar in early pregnancy
The review of literature devoted to the issue of early diagnostics of chorion 
ingrowth into the uterine scar, made by Timor-Tritsch et al. [22], showed that this 
diagnostics is quite complicated. The other authors also note that placental accreta, 
increta or percreta in the first trimester of pregnancy is identified with difficultly 
[4, 24]. The literature refers only to several cases of diagnosed placenta accreta in 
the first trimester of pregnancy [23].
Most publications include information on placentation anomalies in the first 
trimester diagnosed during the morphological examination of the uterus ablated 
because of excessive bleeding that took place during the uterine curettage in early 
pregnancy or within a tardive period after the abortion.
No objective signs of chorion increta into the uterine scar are present.
Chorion increta risk factors (present in past medical history): uterine scar  
(caesarean section or myomectomy), manual ectomy of placenta, multiple gesta-
tion, dilation and curettage, endometriosis, multiple confinement, advanced age of 
the mother, IVF induced pregnancy.
The actual dependence of the chorion/placenta increta frequency on the speci-
fied risk factors remains obscure. The combination of two-three and more factors is 
observed for most cases of placenta percreta [29]. In case of placenta presentation 
to the scar, the ingrowth risk makes 3% after the first caesarean section and reaches 
40% and more after the third similar operation [30].
4.3.1 Ultrasonography
Diagnostics of ovum localisation in the uterine cavity, as viewed by ultraso-
nography, is an integral part of diagnosing uterine pregnancy and usually does not 
present any complexity.
Sonography is a very important instrument for exact location of the gestational 
sac and for diagnosing inadequacy of the postoperative uterine scar.
The ultrasonic signs of chorion ingrowth into the uterine scar in the first trimes-
ter are as follows (Figures 1–4):
• absence of decidual membrane in the area of localisation of the placenta
• low-lying gestational sac (in the scar area)
• invagination of the placenta towards the bladder
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Figure 2. 
Ultrasonographic examination: retroplacental complex (on the left: the scheme; on the right: designated with 
arrows from the left to the right—decidua capsularis, decidua parietalis, decidua basalis; other denotations: 
SAC—gestational sac, FL—fluid-containing space—hypoechogenic line between decidua parietalis and 
decidua basalis).
• hypoechoic inclusions (lacunae) in the placental area
• myometrium thickness in the retroplacental zone below 1 mm
• more intense uterine-placental blood flow.
Sensibility—41%, specificity—88% [19]. For comparison: these indices in the 
second trimester make 60 and 83.5% respectively.
Histopathologically, chorion increta (irrespective of having a uterine scar) is 
characterized by partial or complete absence of decidual membrane, following 
which the placental villi get accreted to the myometrium or invade it (Figure 1).
According to Richardson et al. [31], the “key” to identifying chorion increta lies 
in the retroplacental complex and is characterized by absence of a hypoechogenic 
line (the norm being from 1 to 2 mm), that is, there is a loss of normal decidual 
interaction between the chorion and the myometrium (Figure 2).
The presence of placental lacunae (Figures 3 and 4), according to some authors, 
is the most valuable attribute of placenta increta, with the 89% sensibility, specificity 
of 81%, positive prognostic value of 73% and negative prognostic value of 93% [32], 
while the combination of lacunae and myometrium thickness below 1 mm in the retro-
placental complex zone shows the metrics of 100, 72, 72 and 100% respectively [33].
Figure 1. 
On the left: ultrasonographic examination-absence of decidual membrane in the placental localisation area; 
on the right: histopathological examination—chorionic villi in the myometrium with no decidual membrane 
(haematoxylin, eosin; 100×) [24].
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The uterine scar inadequacy is diagnosed not only and not purely on the basis of 
thinning of the scar and the presence of considerable number of hyperechoic inclu-
sions (connective tissue), but also by exposure of other ultrasonic markers which 
include: visualisation of total defect of the myometrium in the scar projection, in 
the form of a “niche” from the uterine cavity side, reaching the serous membrane; 
or partial defect in the myometrium in the scar projection, in the form of a “niche”, 
with thinning of the lower uterine segment down to 3 mm and below; myometrium 
deformation with retraction from the uterine serous membrane side and a “niche” 
from the uterine cavity side, with thinning of the unchanged myometrium down 
to 3 mm and below; total, subtotal necrosis of the myometrium. The enumerated 
criteria are deemed to be an indication for operative treatment of the inadequate 
uterine scar during the period of periconceptional preparation.
The value of uterine scar thickness indicator or other criteria of inadequacy as 
predictors of uterine rupture and excessive bleeding in the first trimester of preg-
nancy in case of its interruption, has not been studied and is not known. Most of 
the echographic criteria of placenta increta have a real diagnostic value only after 
15 weeks of pregnancy (sensibility—78–93%, after 28 weeks—100%).
In the absence of a clear picture or in case of doubtful ultrasonographic results at 
suspicion on ectopic pregnancy, other methods of research are undertaken.
Figure 3. 
Ultrasonographic examination: on the left—sonogram, grey scale: evagination of the placenta into the bladder; 
on the right—sonogram, colour doppler: visible hypervascularisation between the uterine serous membrane 
and the bladder wall; placental lacunae [34].
Figure 4. 
Ultrasonographic examination: hypoechoic inclusions (lacunae) in the placental area (composite cystophorous 
“aggregate” in the uterine wall) [34].
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4.3.2 Magnetic resonance imaging
To diagnose placenta increta in the second and third trimesters of pregnancy, 
magnetic resonance imaging (MRI) is used in recent years in case of dubious results 
of ultrasonography [22]. However, diagnostics with the help of ultrasonography 
(including colour Doppler) and MRI has not shown a statistically significant differ-
ence [35]. No valid criteria of MRI diagnostics are so far developed.
An observation of a 41-year-old patient with a caesarean section in the past medi-
cal history has been described. The patient had an intra-abdominal haemorrhage on 
the 21st week of pregnancy, without any signs of placental anomalies according to the 
ultrasonography data, whereas the MRI showed a picture of deep placental invasion 
suggesting placenta increta or percreta (Figure 5). Placenta percreta was confirmed 
by the histological examination of the operatively extirpated uterus (ablated in con-
nection with spontaneous uterine rupture during the confinement) [28].
An observation of a 42-year-old patient with vaginal haemorrhage and pain 
in the lower abdomen lasting for 2 weeks after the dilation and curettage, at the 
5-week gestation period, has been described. The level of β-HCG in serum was 
2009.3 mlU/ml. The diagnosis—chorionic increta—was made on the basis of 
magnetic resonance imaging (Figure 6).
The sensibility of magnetic resonance imaging is 77%, the specificity—50% in 
patients with average 30.8 weeks period of pregnancy. The accuracy of diagnosis 
makes 67% [36]. As to the earlier gestation periods, no data were found for the 
specified parameters.
Figure 6. 
Patient R., 42 years old. Magnetic resonance imaging (on the left): A-sagittal T2-weighted MR image (TR/TE 
4000/85 ms) of the pelvic area shows a clearly contoured intramyometric aggregate with high signal intensity. 
B-sagittal T1-weighted MR image (TR/TE 150/4.2 ms)—after intravenous administration of gadolinium-
based contrast medium, shows a hypointense aggregate with focal areas of intensification (the arrows). 
Morphological examination (on the right): Invasion of trophoblast (T) in the myometrium (M), accompanied 
by a haematoma (H) [37].
Figure 5. 
Patient N. aged 41. Magnetic resonance imaging (on the left): (a) sagittal MR image-deep placental invasion 
(the arrow); (b) coronal MR image of placenta (the arrowhead), invasion extending deep into the surrounding 
myometrium (the arrows). Gross specimen (on the right): extirpated uterus [28].
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5.  Management of patients with ingrowth of chorion into the uterine 
scar in case of interrupting pregnancy in early periods
The scientific literature describes a clinical observation [38] of a woman with 
two caesarean section operations in the past history. The reviewed pregnancy 
was third, 11th week. The patient entered the hospital with excessive uterine 
haemorrhage. The nonsurgical arrangements (uterine curettage, etc.) proved to be 
inefficient, therefore she was subjected to hysterectomy. The total blood loss was 
estimated to be 3500–4000 ml. The haemoglobin figure was 8.1 g/dl. Transfusion of 
9 units of erythrocytes and 4 units of fresh frozen plasma was effected. The patient 
recovered from the critical condition and was discharged on 7th day after the opera-
tion. The histopathological examination of the specimen (the extirpated uterus) 
confirmed the diagnosis “placenta accreta”.
Takeda et al. [25] describe a clinical observation of placenta increta in a 27-year-
old woman (three pregnancies and one confinement by caesarean section in the 
past history). The pregnancy under review was non-developing, on 11th week, 
that ended surgically (curettage). Eight weeks after the curettage, haemorrhage 
occurred. The ultrasonography showed localized heterogeneous “aggregates” in the 
myometrium. The increased value of β-HCG in blood serum indicated at the pres-
ence of residual placental tissue. Diagnosis: placenta increta after abortion in the 
first trimester. Actions taken: transcatheter arterial chemoembolisation with dacti-
nomycin for reaching immediate haemostasis and cellulicidal effect on placenta 
tissues. Twenty days after the chemoembolisation, the value of β-HCG in blood 
serum fell to the normal level, and the “aggregate” characterising impairment of the 
uterus according to the ultrasonography data disappeared without complications.
The clinical observation described by Chou et al. [39] in respect of a 35-year-old 
woman with continual vaginal haemorrhage and preceding caesarean section in 
anamnesis, demonstrated a diagnosed 7th week pregnancy. The ovum with dimen-
sions of 2.5 × 1.5 cm was located within the area of a uterine scar from the previous 
caesarean section. The original treatment was one-time injection of Methotrexate. 
Nevertheless, β-HCG levels remained high, and the transvaginal ultrasonography 
showed signs of continuing pregnancy. Consequently, hysteroscopic resectoscopy 
Figure 7. 
Patient S., 40 years old. Diagnosis: pregnancy, 13 weeks. Caesarean section in the past medical history. Ingrowth 
of chorionic villi into the uterine scar. Laparotomy. It was found as wellas a fundal uterine defect of 4 ± 3 cm 
with placental tissue penetrating through the uterine serosa. Hysterectomy. Histology of the placenta showing 
the myometrium (1) with invasions of chorionic villi (2) and trophoblast cells (3) (x20; haematoxylin – eosin 
staining) [38].
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was made during which the gestational tissue was completely removed. This did not 
entail any intra- or postoperative complications. The level of β-HCG in blood serum 
returned to normal 4 weeks after the operation. According to the authors, the 
hysteroscopic ectomy of ingrown chorion residues can be regarded as primary treat-
ment, and as a secondary option-after an unsuccessful attempt of treatment with 
Methotrexate [39]. Histopathology of the placenta is shown in Figure 7, performed 
on a 40-year-old patient with a uterine rupture at 13 weeks of gestation, described 
by the authors A. Esmans et al. [38].
Lim et al. [24] give a clinical observation of placenta accreta and tardive haemor-
rhage in a patient aged 41 with five pregnancy episodes in the past medical history 
(1—confinement, 1—caesarean section for presentation of placenta and 3 curettage 
manipulations). Placenta accreta caused vaginal haemorrhage 3 years after the 
abortion, in the first trimester, 5 weeks’ period. Originally the patient had regular 
menstruation, further the menses became irregular and heavy within the last year, 
which was the reason to seek medical attention. The level of serous β-HCG was  
0.27 mIU/mL. The ultrasonography failed to visualize the endometrium line. 
Originally, endometrium cancer or uterine myoma with necrosis of the node was 
suspected. Actions taken: curettage; subsequently, in connection with the continu-
ing haemorrhage-hysterectomy. The histopathological examination evidentiated 
the placenta tissue having no atypical trophoblast cells [24].
6.  Recommendations for interruption of pregnancy in women with 
localisation of chorion/placenta in the uterine scar area after the 
caesarean section
The optimal treatment of patients in the first trimester of pregnancy with 
sonographic diagnosis of suspected chorion increta into the uterine scar remains 
uncertain. The suggested options include one principal type of treatment or its 
combination with other methods, like curettage, systemic or local administration of 
Methotrexate, hysteroscopy, laparotomy and uterine artery embolisation [22, 40].
A review by Timor-Tritsch and Monteagudo [22] analyses the structure of 
surgical interferences in 44 patients with the given diagnosis: 5 of them (10.6%) 
underwent uterine arteries embolisation; 38 (78.7%) were subjected to laparotomy; 
35 of the latter (74.4%) to hysterectomy; 1 patient of this group was diagnosed with 
arteriovenous malformation after the dilation and curettage and was subjected to 
embolisation that subsequently ended in hysterectomy [22].
The sporadic, mainly individual, cases and their results are insufficient to draw 
a definite conclusion as to which of the performed interference methods is the most 
effective. It is almost impossible to identify what type of treatment entails maxi-
mum number of complications and should be avoided. Gynaecologists, as a rule, 
undertake curettage, laparoscopy and hysteroscopy, deeming them preferable as the 
“first-line” approach.
Nevertheless, the following recommendations were made on the basis of the 
meta-analysis [22]:
• If possible, dilation and curettage should be avoided because this might entail 
excessive bleeding, repeated curettage (for the haemostatic purpose) with no 
effect, blood transfusion, and in many cases—laparotomy and loss of uterus.
• Systemic administration of Methotrexate as the only method of treatment 
should be avoided. The argument: lengthy expectation of the effect or its 
absence results in further growth of the embryo and vascularisation of the 
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gestational sac; therefore the subsequent, “second line” of therapy may be 
accompanied by considerable complications.
• Uterine artery embolisation as a primary treatment should be used cautiously 
or not be used at all. Lengthy expectation of haemostasis or the haemorrhage 
fadeout can delay more effective primary treatment which could help in a 
faster manner or might allow avoiding of hysterectomy.
• Surgical exsection of the impairment area through hysteroscopic method, as 
well as transvaginal or transabdominal local administration of Methotrexate 
with or without additional intramuscular dose of this medication, appears to 
be the optimal means in terms of minimisation of frequency of complications.
7. Conclusion
Interruption of pregnancy in case of a uterine scar can be effected at any 
pregnancy period using any method; at the same time, no additional risks for the 
mother are described if the ovum is localized beyond the scar zone.
Ultrasonic examination is an important method for viewing possible ovum 
presentation to the scar and possible chorion increta into the scar.
At suspicion on chorion ingrowth into the uterine scar, dilation and curettage, 
systemic administration of Methotrexate, uterine artery embolisation should be 
avoided, while it is recommended to give preference to combined methods— 
surgical exsection of the impairment zone through hysteroscopic access and local 
administration of Methotrexate.
In all cases, patients with the uterine scar (irrespective of localisation of the 
ovum) are subject to hospitalisation for interruption of pregnancy at any period.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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